Spero Therapeutics: Replay of R&D Day on Non-Tuberculous Mycobacteria Pulmonary Disease (NTM-PD) and Spero’s SPR720 Program
About The Event
The virtual R&D Day features a presentation by key opinion leader Kevin L. Winthrop, MD, MPH (Division of Infectious Disease, OHSU Medical School).
During his presentation, Dr. Winthrop discusses the etiology, unmet medical need, and treatment landscape of NTM-PD. Members of the Spero management team provide an overview of the development program for SPR720, a potential novel first line oral therapy for NTM infections.
A live Q&A session follows the formal presentations.